Hi @LightForce I don't disagree at all with those numbers being...

First 39 Last

jord@n

503 Posts.

21/08/18

11:19

Post #: 35058716

Originally posted by LightForce ↑

Column 1 Column 2 Column 3 Column 4

1 FY18 FY19 (Target) Comments/Assumptions

2 Revenue $878.70 $949.00 Assume 8% increase in revenue

3 Underlying EBITDA $97.60 $105.43 Assume same underlying EBITDA Margin

4 Underlying EBITDA Margin 11.11% 11.11%

5 Interest $14.20 14.19 4.7% interest rate on $302M debt. Assume no increase in further debt as cash flow from operations is enough to cover capex requirements.

6 Depreciation & Amortisation $27.90 $29 Assume slight increase in D&A.

7 Net Cash from Ops $65.6 Assume CFO is enough to cover capex ($74M capex in FY18 but will reduce to $50M).

8 Capex $70 $50

9 Profit Before Tax $62

10 Tax $19 Assume 30% (should be less than 30% in FY19)

11 NPAT $44 This has not taken into account the $10-$13M cost reduction, which will then increase the EBITDA Margin.

The news that will appear next August is: Greencross has increased profit by 112% for FY19!

Expand

Hi @LightForce

I don't disagree at all with those numbers being very possible. My more prudent profit target factors in a margin of safety to reduce downside risk, as I'm always happy to be surprised on the upside!

GXL Price at posting: $4.02 Sentiment: Sell Disclosure: Not Held

Upvote

0 Great analysis

Top Stories

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

HotCopper Highlights: Your most watched stocks for Week 47, 2024

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

There are more pages in this discussion • 1 more message in this thread...

First 39 Last

Add GXL (ASX) to my watchlist

	Column 1	Column 2	Column 3	Column 4
1		FY18	FY19 (Target)	Comments/Assumptions
2	Revenue	$878.70	$949.00	Assume 8% increase in revenue
3	Underlying EBITDA	$97.60	$105.43	Assume same underlying EBITDA Margin
4	Underlying EBITDA Margin	11.11%	11.11%
5	Interest	$14.20	14.19	4.7% interest rate on $302M debt. Assume no increase in further debt as cash flow from operations is enough to cover capex requirements.
6	Depreciation & Amortisation	$27.90	$29	Assume slight increase in D&A.
7	Net Cash from Ops	$65.6		Assume CFO is enough to cover capex ($74M capex in FY18 but will reduce to $50M).
8	Capex	$70	$50
9	Profit Before Tax		$62
10	Tax		$19	Assume 30% (should be less than 30% in FY19)
11	NPAT		$44	This has not taken into account the $10-$13M cost reduction, which will then increase the EBITDA Margin.

Hi @LightForce I don't disagree at all with those numbers being...

Top Stories

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

HotCopper Highlights: Your most watched stocks for Week 47, 2024

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Sales growth pushes Lovisa's fortunes (and shares) upwards

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

Featured News